Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNE-101 in Myotonic Dystrophy Type 1
NCT05481879Phase 2Active, not recruiting
- Sponsor
- Dyne Therapeutics
- Start
- Sep 2022
- Primary completion
- Jul 2029
- Modality
- Antibody Conjugates, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 2 trial of zeleciment basivarsen in myotonic dystrophy type 1 (DM1), sponsored by Dyne Therapeutics. Started Sep 2022; status: active, not recruiting.
02
Drugs
zeleciment basivarsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT05481879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481879.